[-] Show simple item record

dc.contributor.authorWong, Longen_US
dc.contributor.authorCriswell, Danen_US
dc.date.issued2009-12
dc.description.abstractNo data are available to support the addition or substitution of warfarin after failure of antiplatelet agents for secondary prevention of ischemic stroke. Further, warfarin may be no better than placebo at reducing the risk of noncardioembolic stroke. (Strength of recommendation [SOR] B, based on heterogeneous meta-analyses.)en_US
dc.identifier.citationEvidence Based Practice 12(12): 01-02.en_US
dc.identifier.urihttp://hdl.handle.net/10355/7655
dc.publisherFamily Physicians Inquiries Networken_US
dc.relation.ispartofEvidence Based Practice 12(12): 01-02.en_US
dc.relation.ispartofcollectionEvidence Based Practice, 2009en_US
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. Evidence Based Practice.en_US
dc.subjectthrombotic occlusionen_US
dc.subjectaspirin therapyen_US
dc.subject.lcshThrombosisen_US
dc.subject.lcshAspirin -- Therapeutic useen_US
dc.titleWarfarin therapy not warranted for secondary prevention of CVDen_US
dc.typeArticleen_US


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record